Low-carb breakfast aids glucose measures with diabetes
Jun 22, 2023
The analysis included 121 participants randomly assigned to a low-carb or low-fat breakfast for three months.
Sliding scale insulin for diabetic residents: Is it helpful or harmful?
By
Jered Yalung, PharmD
May 18, 2023
Emphasis needs to be put on diabetes management in both facilities and in homes.
Medicare Diabetes Prevention telehealth program expected to continue through 2023
By
John Roszkowski
May 02, 2023
The Medicare Diabetes Prevention Program’s telehealth capabilities will not cease when the public health emergency is allowed to sunset in nine days, allowing program providers more time to resume in-person...
Sugar-sweetened beverage intake linked to mortality, CVD in T2D
Apr 20, 2023
An increased hazard ratio was noted for all-cause mortality, cardiovascular disease incidence and mortality for higher sugar-sweetened beverage intake.
Mortality reduced with adherence to low-carb diet in type 2 diabetes
Mar 24, 2023
Lower mortality was seen with increases in total, vegetable and healthy low-carbohydrate diet scores.
Novo Nordisk to cut insulin prices by up to 75 percent
Mar 14, 2023
The news follows a similar move made by Eli Lilly, which said earlier this month that it will cut insulin prices by 70%.
The necessity of clean tech and indoor air quality in assisted living
By
Tony Abate
Jan 12, 2023
Owners and operators who take advantage of indoor air quality technology can support lower vacancy rates, improve health and safety for residents and drive public and stakeholder confidence.
Low-carbohydrate, high-fat diet beneficial in T2DM in short term
Dec 12, 2022
Greater improvements were seen in glycemic control and weight loss than with a high-carbohydrate, low-fat diet for persons with T2DM.
SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
Dec 07, 2022
SGLT-2is are associated with the lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists and metformin.
AHA: Lowering TGs with pemafibrate does not cut cardiovascular risk in type 2 diabetes
Nov 08, 2022
In patients with type 2 diabetes, hypertriglyceridemia and low HDL cholesterol levels, the risk for cardiovascular events was not lower with pemafibrate versus placebo.